May 06, 2024 / 02:00AM GMT
Matthew Wright - NWR Communications - Director
Hello and welcome to this Neurotech investor webinar discussing today's announcement from the company on its Phase I/II Rett Syndrome trial results. (Operator Instructions) Please note, this session is being recorded.
On behalf of Neurotech today, we have the Executive Director, Dr. Thomas Duthy. I'll now hand it over to you. Please go ahead.
Thomas Duthy - Neurotech International Ltd - Executive Director
Thank you, Matt. And thanks everyone for joining. It's nice to reconnect on some additional clinical data we have for you today in Rett Syndrome, having only spoken to, I assume, some of you a couple of weeks ago with the results of our Phase II/III autism clinical trial in pediatric patients. So it's been a very, very busy month for the company, and we're delighted to share with you today the very exciting results we've seen today for our Rett Syndrome Phase I/II clinical trial.
This is just a disclaimer. There will be forward-looking statements made today in this presentation that has been
Neurotech International Ltd Rett Syndrome Phase I Or II Trial Results Webinar Transcript
May 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers